SEC Comment Letter for Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) (ARMP) — Apr 13, 2017
Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)
Date: April 13, 2017 · CIK: 0000921114 · Accession: 0000000000-17-012808
AI Filing Summary & Sentiment
Reasoning
Letter
April 13, 2017 M. Scott Salka Chief Executive Officer AmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 AmpliPhi Biosciences Corporation Registration Statement on Form S-1 Filed April 6, 2017 File No. 333-217169Re: Dear Mr. Salka: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Josh Samples at (202) 551-3199 with any questions. Division of Corporation Finance Office of Healthcare and Insurance cc: Asa Michael Henin
Show Raw Text
April 13, 2017
M. Scott Salka
Chief Executive Officer
AmpliPhi Biosciences Corporation
3579 Valley Centre Drive, Suite 100
San Diego, CA 92130
AmpliPhi Biosciences Corporation
Registration Statement on Form S-1
Filed April 6, 2017
File No. 333-217169Re:
Dear Mr. Salka:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Josh Samples at (202) 551-3199 with any questions.
Division of Corporation Finance
Office of Healthcare and
Insurance
cc: Asa Michael Henin